Longitudinal studies of putative growth hormone (GH) biomarkers and hematological and steroidal parameters in relation to 2 weeks administration of human recombinant GH.
Adult
Athletes
Biomarkers
/ analysis
Dihydrotestosterone
/ blood
Doping in Sports
/ methods
Fibronectins
/ blood
Human Growth Hormone
/ analysis
Humans
Insulin-Like Growth Factor I
/ analysis
Longitudinal Studies
Male
Recombinant Proteins
/ analysis
Steroids
/ analysis
Testosterone
/ blood
Vitamin D-Binding Protein
/ blood
DHT
alpha-HS-glycoprotein
athlete biological passport
fibronectin 1
growth hormone
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
20
10
2019
revised:
27
02
2020
accepted:
28
02
2020
pubmed:
3
3
2020
medline:
1
4
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
The detection of low doses of recombinant growth hormone is a challenge in antidoping testing. Future testing may lead toward the longitudinal monitoring of IGF-I and P-III-NP in an endocrine module. Additional biomarkers, for example vitamin D binding protein, alpha-HS-glycoprotein, fibronectin 1, and decorin have been identified in different omics studies. This was a longitudinal study of the usefulness of these putative biomarkers in relation to 2 weeks administration of low doses of recombinant growth hormone in healthy male volunteers. Moreover, the hematological parameters included in the athlete biological passport were studied as well as the serum concentration of testosterone and dihydrotestosterone. Fibronectin 1 increased by 20% during the treatment period (P ˂ 0.05), confirming the previous finding. Alpha-HS-glycoprotein decreased by 25% up to 3 weeks after treatment (P ˂ 0.05), contradicting previous results. The addition of fibronectin 1 increased the likelihood of detecting recombinant growth hormone intake based on individual calculated thresholds in some of the participants compared with the GH2000, IGF-I, and P-III-NP. The multiplication of fibronectin 1 concentration by IGF-I resulted in the most profound (up to 4-fold) changes. A minor 15% increase (P = 0.003) in the reticulocyte percentage was observed, but the changes did not lead to any atypical profile based on individual passport thresholds. Vitamin D binding protein, decorin, testosterone, and dihydrotestosterone were not affected by growth hormone. Dihydrotestosterone sulfate was negatively correlated with IGF-I at baseline (R = -0.50, P = 0.003) and post dose (R = -0.59, P = 0.01). In conclusion, fibronectin 1 was verified as a promising future biomarker for detecting low doses of recombinant growth hormone.
Substances chimiques
Biomarkers
0
FN1 protein, human
0
Fibronectins
0
GC protein, human
0
Recombinant Proteins
0
Steroids
0
Vitamin D-Binding Protein
0
Dihydrotestosterone
08J2K08A3Y
Human Growth Hormone
12629-01-5
Testosterone
3XMK78S47O
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-719Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
Bidlingmaier M, Suhr J, Ernst A, et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem. 2009;55(3):445-453.
Holt RI, Bohning W, Guha N, et al. The development of decision limits for the GH-2000 detection methodology using additional insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Drug Test Anal. 2015;7(9):745-755.
Erotokritou-Mulligan I, Bassett EE, Kniess A, Sonksen PH, Holt RI. Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth Horm IGF Res. 2007;17(5):416-423.
Saugy M, Robinson N, Saudan C, Baume N, Mangin LAP. Human growth hormone doping in sport. Br J Sports Med. 2006;40(Suppl 1):i35-i39.
Marchand A, Buisson C, Martin L, Martin JA, Molina A, Ressiot D. Report on an anti-doping operation in Guadeloupe: high number of positive cases and inferences about doping habits. Drug Test Anal. 2017;9(11-12):1753-1761.
Sottas PE, Vernec A. Current implementation and future of the athlete biological passport. Bioanalysis. 2012;4(13):1645-1652.
Lehtihet M, Bhuiyan H, Dalby A, Ericsson M, Ekstrom L. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks’ administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers. Drug Test Anal. 2019;11(3):411-421.
Marchand A, Martin JA, Collot D, et al. Combined administration of microdoses of growth hormone and erythropoietin: effects on performance and evaluation of GH detection capability using anti-doping methods. Drug Test Anal. 2019;11(11-12):1698-1713.
Ponzetto F, Mehl F, Boccard J, et al. Longitudinal monitoring of endogenous steroids in human serum by UHPLC-MS/MS as a tool to detect testosterone abuse in sports. Anal Bioanal Chem. 2016;408(3):705-719.
Handelsman DJ, Bermon S. Detection of testosterone doping in female athletes. Drug Test Anal. 2019;11(10):1566-1571.
Schumacher YO, Saugy M, Pottgiesser T, Robinson N. Detection of EPO doping and blood doping: the haematological module of the athlete biological passport. Drug Test Anal. 2012;4(11):846-853.
Pottgiesser T, Echteler T, Sottas PE, Umhau M, Schumacher YO. Hemoglobin mass and biological passport for the detection of autologous blood doping. Med Sci Sports Exerc. 2012;44(5):835-843.
Blok GJ, de Boer H, Gooren LJ, van der Veen EA. Growth hormone substitution in adult growth hormone-deficient men augments androgen effects on the skin. Clin Endocrinol (Oxf). 1997;47(1):29-36.
Christ ER, Cummings MH, Westwood NB, et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab. 1997;82(9):2985-2990.
Sohmiya M, Kato Y. Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency. Clin Endocrinol (Oxf). 2001;55(6):749-754.
Tan SH, Lee A, Pascovici D, et al. Plasma biomarker proteins for detection of human growth hormone administration in athletes. Sci Rep. 2017;7(1):1-2.
Ferro P, Ventura R, Perez-Mana C, Farre M, Segura J. Genetic and protein biomarkers in blood for the improved detection of GH abuse. J Pharm Biomed Anal. 2016;128:111-118.
Bahl N, Stone G, McLean M, Ho KKY, Birzniece V. Decorin, a growth hormone-regulated protein in humans. Eur J Endocrinol. 2018;178(2):147-154.
Elmongy H, Masquelier M, Ericsson M. Development and validation of a UHPLC-HRMS method for the simultaneous determination of the endogenous anabolic androgenic steroids in human serum. J Chromatogr A. 2020;1613:460686. Epub 2019 Nov 6.
(BSS) BSS. Blood stability score (BSS). 2017 Available at https://www.wada-ama.org/en/questions-answers/blood-stability-score-bss.
Sottas PE, Robinson N, Saugy M. The athlete's biological passport and indirect markers of blood doping. Handb Exp Pharmacol. 2010;195:305-326.
Merchav S. The haematopoietic effects of growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab. 1998;11(6):677-685.
Miyagawa S, Kobayashi M, Konishi N, Sato T, Ueda K. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol. 2000;109(3):555-562.
Mancini A, Imperlini E, Alfieri A, et al. DHT and IGF-1 in peripheral blood lymphocytes: new markers for the biological passport of athletes. J Biol Regul Homeost Agents. 2013;27(3):757-770.
Ferro P, Ventura R, Perez-Mana C, Farre M, Segura J. Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. Drug Test Anal. 2017;9(7):1011-1016.
Ding J, Okada S, Jorgensen JO, Kopchick JJ. Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects. Proteomics. 2011;11(17):3565-3571.
Tang L, Bernardo O, Bolduc C, Lui H, Madani S, Shapiro J. The expression of insulin-like growth factor 1 in follicular dermal papillae correlates with therapeutic efficacy of finasteride in androgenetic alopecia. J Am Acad Dermatol. 2003;49(2):229-233.
Zhao J, Harada N, Okajima K. Dihydrotestosterone inhibits hair growth in mice by inhibiting insulin-like growth factor-I production in dermal papillae. Growth Horm IGF Res. 2011;21(5):260-267.
Mullen J, Borjesson A, Hopcraft O, et al. Sensitivity of doping biomarkers after administration of a single dose testosterone gel. Drug Test Anal. 2018;10(5):839-848.